Zenas BioPharma, Inc.
Zenas BioPharma, Inc. is listed today as Zenas BioPharma, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2024 | $200 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Zenas BioPharma, Inc., its revenue in fiscal 2025 came from these business segments: Single Reportable $10 million (100%).
Annual report (SEC XBRL) · Dec 2025
Zenas BioPharma, Inc. chose not to state its revenue in its newest notice of a funding round (May 2024).
SEC Form D · May 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2024
Products and services#
No products or services of Zenas BioPharma, Inc. are on record.
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Enavate Sciences GP, LLC | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Fairmount Funds Management LLC | Fund or asset manager | not stated | not stated | Held Series Seed, A, B and C preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
| Fairmount Healthcare Fund II L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A, B and C preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
| Leon O. Moulder Jr. | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2024) | SEC Form 3 |
| SR One Capital Management, LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Zebra Aggregator, LP | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 26 investors.
Largest shareholders today
Institutions holding Zenas BioPharma, Inc. shares, as of Sep 30, 2026.
- FMR LLC$264 M14.44%
- Wellington Management Group LLP$218 M11.94%
- SR One Capital Management, LP$136 M7.43%
- NEA Management Company, LLC$109 M5.93%
- BlackRock, Inc.$90 M4.91%
- Federated Hermes, Inc.$84 M4.58%
- Capital International Investors$79 M4.31%
- Enavate Sciences GP, LLC$79 M4.30%
- Polar Capital Holdings Plc$65 M3.55%
- Royalty Pharma Sub-Manager, LLC$64 M3.52%
- Fairmount Funds Management LLC$64 M3.50%
- State Street Corp$51 M2.78%
- NVP Associates, LLC$50 M2.71%
- Vanguard Capital Management LLC$46 M2.54%
- Price T Rowe Associates Inc /MD/$29 M1.60%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jennifer Jacob Fox | Executive officer | May 2024 |
| Joseph O. Farmer | Executive officer | May 2024 |
| Leon O. Moulder, Jr. | Executive officer | May 2024 |
| Tanya Z. Fischer | Executive officer | May 2024 |
| Hongbo O. Lu | Director | May 2024 |
| Jake Jacob Nunn | Director | May 2024 |
| James Patrick Boylan | Director | May 2024 |
| John Jacob Orloff | Director | May 2024 |
| Leon O. Moulder, Jr. | Director | May 2024 |
| Patricia Jacob Allen | Director | May 2024 |
| Patrick Gerald Enright | Director | May 2024 |
| Tim Jacob Xiao | Director | May 2024 |
| Tomas O. Kiselak | Director | May 2024 |
Went public since 2024. Its SEC number is that of a company listed on a stock exchange.